

Clinical Practice Guideline For

Periodontics











INTRODUCTION:

Periodontal Diseases. This term, in its widest sense, includes all pathological conditions of the periodontium. It is however, commonly used with reference to those inflammatory disease which are plaque induced and which affect the marginal periodontium: **Periodontitis and Gingivitis**

Gingivitis:

Gingivitis is the mildest form of periodontal disease. It involves inflammation confined to the gingival tissues.






- There is no loss of connective tissue attachment
- A gingival pocket may be present

Periodontitis:

Is the apical extension of gingival inflammation to involve the supporting tissues. Destruction of the fibre attachment results in periodontal pockets.

- · it leads to loss of connective tissue attachment
- which in turn results in loss of supporting alveolar bone





OBJECTIVES OF TREATMENT

- Relief of symptoms
- Restoration of periodontal health
- Restoration and maintenance of function and aesthetic



PERIODONTAL ASSESSMENT

Assessment of medical history Assessment of dental history Assessment of periodontal risk factors

- 1. Age
- 2. Gender
- 3. Medications
- 4. Presence of plaque and calculus (quantity and distribution)
 - 5. Smoking
 - 6. Race/Ethnicity
 - 7. Systemic disease (eg, diabetes)
 - 8. Oral hygiene
 - 9. Socio-economic status and level of education



Assessment of extra-oral and intraoral structures and tissues Assessment of teeth

- 1. Mobility
- 2. Caries
- 3. Furcation involvement
- 4. Position in dental arch and within alveolus
- 5. Occlusal relationships
- 6. Evidence of trauma from occlusion

Assessment of periodontal soft tissues


- 1. Colour
- 2. Contour
- 3. Consistency (fibrotic or oedematous)
- 4. Presence of purulence (suppuration)
- 5. Amount of keratinized and attached tissue gingiva
 - 6. Probing depths
 - 7. Bleeding on probing
 - 8. Clinical attachment levels
 - 9. Presence and severity of gingival recession




Radiographic evaluation:

This is useful in the evaluation of alveolar bone loss, bone density, furcations, root shape, and proximity, etc. It reveals the extent of bony involvement (bone loss), sub-gingival calculus, restorations and other pathologies that are present in the bone and teeth.





The Treatment of Periodontal Disease



Prophylaxis/ Scaling:



- It involves scaling calculus above the gum line followed by ordinary flossing, and pumice polishing using a rubber cup on a slow speed hand piece.
- A prophylaxis is performed only on patients with little bone loss and only minor, localized pocketing.
- With a pocketing of <3mm




Debridement/ Root planing:

- A full mouth debridement involves supra and sub- gingival scaling to remove the bulk of the calculus and plaque from the teeth
- Root planing is a specific treatment that removes the roughened cementum and surface dentin that is impregnated with calculus, microorganisms and their toxins
- This is often done under local anaesthesia.




Type I (Gingivitis)



- Type I periodontal disease is characterized by swollen and red gums (gingivitis).
- Presence of pseudo pocketing.
- If there is substantial buildup of calculus in the sulcus, the treatment of choice is a full mouth debridement followed by a second prophylaxis visit (referred to as a fine scale).

Type II (early or mild) Periodontal Disease



- In type II periodontal disease, some bone loss has occurred.
- Pocketing area at most 3-4 mm deep.
- As with type I disease, the first line of treatment always involves a
 debridement visit followed by the thorough removal of all calculus
 and plaque under local anesthesia.
- This type of scaling is called a root planing.

Type II (moderate periodontitis)





- The In moderate periodontitis, pocket depths (or attachment loss) are 4 to 6 mm, with BOP and sometimes slight mobility.
- These cases are also treated with an initial debridement visit followed by several visits for scaling and root planing procedures.
- Unfortunately, because of the loss of the bone, the pockets may not subside all the way back to normal. Floss may not be able to reach all the way down to the base of the pocket

Type III (severe) Advanced Periodontal Disease







- Type IV periodontal disease is much more serious than either of the other two types because the bone loss is so much more pronounced.
- The major difficulty here is that the bony pockets will not rebuild, and it becomes very difficult to reach all the way to the bottom of the infrabony pockets to clean them.
- In most of these cases, patients are referred to a Periodontist for periodontal surgery.

Type (refractory) periodontal disease

- Same clinical signs as Advanced but includes adolescents or young adults
- Localized Or generalized
- Rapid cycles of disease
- Patients in this category may start out with mild to moderate periodontitis, follow through with treatment for each stage,
- carry out all home care procedures along with routine periodontal scaling every 3-4 months

Antibiotics and antibiotic delivery systems



"Antibiotic therapy has been helpful as an adjunctive therapy <u>in addition</u> to root planing and good daily hygiene".

Systemic Antibiotic:

Doxycycline [and Metronidazole (Flagyl)]

- **Doxycycline** (minocycline) is a long acting form of tetracycline.
- It has an affinity for dermal structures so it tends to concentrate in the skin, teeth and gingivae.
- Doxycycline has both antibiotic properties and the ability to block the action of **collagenase** which is an enzyme that is produced by plaque organisms and is partly responsible for the dissolution of the connective tissue which makes up gum tissue.
- Azythromycin is another antibiotic that is recently proven to be very effective in the treatment of periodontal disease

Local Antibiotic:

Arestin

Is a form of antibiotic that is actually injected into a periodontal pocket.

Atridox

It too is a method for delivering doxycycline. It is applied as a gel that conforms to the teeth and gums and then solidifies. Its effects are less long lasting than Arestin, but lasting enough to be of use during the healing phases after surgery.

Actisite

Is a thin thread similar to dental floss, which is treated with tetracycline hydrochloride. This thread is placed into the periodontal pockets around the roots of the teeth after a root planning.

General Overview of the Major Steps in a Typical Periodontal Treatment Plan.



Sequence of Major Phases

- 1. Address acute periodontal problems and/or pain
- 2. Review and update medical and dental histories
- 3. Assessment of systemic risk factors and refer for medical consultation as needed
- 4. Extra-oral examination
- 5. Oral cancer evaluation
- 6. Assessment of periodontal risk and modifying factors
- 7. Periodontal examination to include dental implants
- 8. Dental examination to include occlusal relationships and dental implants
- 9. Radiographic examination
- 10. Establish a definitive diagnosis
- 11 Generate a diagnosis-driven periodontal treatment plan and sequence of treatment

- 12. Determine required adjunctive restorative, prosthetic, orthodontic, and/or endodontic treatments and sequence
- 13. Execute Phase I therapy (aka anti-infective or nonsurgical therapy) with consideration given to adjunctive use of chemotherapeutic agents
- 14. Re-evaluation (assessment) of Phase I therapy
- 15. If end-points are not achieved, consider selective retreatment, need for surgical therapy, specialty referral, or use of adjunctive diagnostic aides, eg, microbial, genetic, medical lab tests, etc.
- 16. Determine interval for periodontal maintenance and continued assessment of periodontal status.

Periodontal Diagnostic Guidelines.

Table 1:

Case Indicator	Healthy	Gingivitis	
Book at Book	Barrier and the Land	Barrier and the Land	
Pocket Depth	[less than or equal to] 3 mm	[less than or equal to] 4 mm	
Bleeding Upon Probing	No	Yes	
Six-Point Probing	Yes	Yes	
Bone Loss	None	None	
Tooth Mobility	None	None	
Furcation	None	None	
Clinical Attachment Loss(CAL)	None	None	
Other	No Inflammation	Only Gingival Tissues affected by	
		inflammatory Process	
		No alveolar bone loss	
		Localized or generalized	
	TREATMENT MODALITY		
Assessment	Prophylaxis/ OHI	Prophylaxis/OHI	
Active Therapy	Prophylaxis	Prophylaxis	
	ОНІ	ОНІ	
Ongoing	6 Months	6 Months	
Maintenance	Prophylaxis/OHI	Prophylaxis/OHI	

Table 2.

Case	Slight chronic	Moderate chronic	Advanced	Aggressive/
<u>Indicator</u>	<u>Periodontitis</u>	<u>Periodontitis</u>	<u>Periodontitis</u>	Retractory
				(Not included)



Pocket Depth	4-5 mm	5-6 mm	[Greater than or Equal to] 6mm	[Greater than or Equal to] 6mm
Bleeding Upon Probing	Yes	Yes	Yes	Yes
Six-Point Probing	Yes	Yes	Yes	Yes
Bone Loss	[less than or equal to] 10%	[less than or equal to] 33%	[Greater than or Equal to] 33%	[Greater than or Equal to] 33%
Tooth Mobility	None	[less than or equal to] Grade II	[less than or equal to] Grade III	[less than or equal to] Grade III
Furcation	< Grade I	[less than or equal to] Grade II	[less than or equal to] Grade III or IV	[less than or equal to] Grade III or IV
Clinical Attachment Loss (CAL)	1-2 mm CAL	3-4 mm CAL	[Greater than or Equal to] 5mm CAL	[Greater than or Equal to] 5mm CAL
Other	Signs of inflammation may be present, including: -Edema -Redness Suppuration -Alveolar bone level is 3-4 mm from CEJ -Radiographic bone loss present -Localized or generalized	Signs of inflammation may be present, <i>including:</i> -Edema -Redness -SuppurationAlveolar bone level is 4-6 mm from CEJ -Radiographic bone loss present -Localized or generalized	Signs of inflammation present, <i>including:</i> -Edema -Redness -SuppurationAlveolar bone level is [Greater than or equal to] 6 mm from CEJ -Radiographic bone loss present -Localized or generalized progression	Signs of inflammation present, <i>including:</i> -Edema -Redness -SuppurationSame clinical signs as Advanced but includes adolescents or young adults -Localized or generalized -Rapid cycles of disease

TREATMENT MODALITY				
Case	<u>Slight</u>	<u>Moderate</u>	Advanced	Aggressive/
<u>Indicator</u>	<u>Periodontitis</u>	<u>Periodontitis</u>	<u>Periodontitis</u>	<u>Refractory</u>
Assessment	-Comp. Oral	-Comp. Oral	-Comp. Oral	-Comp. Oral Evaluation
	Evaluation	Evaluation	Evaluation	-Comp. Perio Evaluation
	-Comp. Perio	-Comp. Perio	-Comp. Perio	-X- rays (bitewing & OPG)
	Evaluation	Evaluation	Evaluation	-Occlusal Analysis
	-X-rays	-X- rays	-X- rays	-Full Mouth Debride



	(bitewing & OPG)	(bitewing & OPG)	(bitewing & OPG)	
	-Occlusal Analysis	-Occlusal Analysis	-Occlusal Analysis	
	Full mouth Debride	-Full Mouth	-Full Mouth Debride	
		Debride		
Active	-Quadrant SRP	-Quadrant SRP	-Quadrant SRP	-Specialty Referral
Therapy	-Localized SRP	-Localized SRP	-Localized SRP	
	-Locally	-Locally	-Locally	
	Administered	Administered	Administered	
	Antimicrobials	Antimicrobials	Antimicrobials	
	-OHI	-OHI	-OHI	
	-Specialty	-Specialty	-Specialty	
	Referral	Referral	Referral	
Ongoing	-Perio	-Perio	-Perio Maintenance-	-Perio Maintenance3/4/6
Maintenance	Maintenance	Maintenance	-3/4/6 months	months
	3/4/6 months	3/4/6 months	-OHI	-OHI
	-OHI	-OHI	-Locally	-Locally
	-Locally	-Locally	-Administered	-Administered
	-Administered	-Administered	Antimicrobials	Antimicrobials
	Antimicrobials	Antimicrobials	-Localized SRP	-Localized SRP
	-Localized SRP	-Localized SRP		

SRP- Simple Root Planing

Level of Management by Cadre to be determined.

Equipment and Instrument Needed.

- Periodontal probes
- Hand Scalers
- Prophylaxis machine with Tips

References:

- 1. Grant, DS, Stern IB, **Periodontics**, 6th Edition, CV Mosby and Co. St. Louis 1988.
- 2. Giusto, T. Non-surgical vs. surgical periodontal therapy, SUNY Stonybrook, June 1997, page 1
- 3. W M M Jenkins, C J Allan, Peridontitics A Synopsis, Reed Educational, 1999.
- 4. <u>www.clinicalperiodontology.com</u>



- 5. (Adapted from Newman MG, Takei H, Klokkevold PR, Carranza FA. Carranzas Clinical Periodontology 10th ed. Philadelphia, PA: Elsevier; 2006.)
- 6. (Adapted from Newman MG, Takei H, Klokkevold PR, Carranza FA. Carranza's Clinical Periodontology 10th ed. Philadelphia, PA: Elsevier, 2006.)
- 7. (Adapted from Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol1999; 4(1):1-6

AKNOWLEDGEMENT:

This document is prepared and compiled by Dr Shika Singh and Dr Ilaitia Lewenilovo, Principal Dental Officer, Lautoka Hospital.

ANNEX

DEFINITIONS & CLASSIFICATIONS

- (a) Excluding gingival overgrowth and recession
- (b) Bleeding upon probing may not be present in individuals with periodontal disease who are smokers.
- (c) **Tooth Mobility:**

Grade I: Slightly more than normal;

Grade II: Moderately more than normal;

Grade III: Severe mobility faciolingually and mesiodistally, combined with vertical displacement.



(d) Furcation Grades:

Grade I: Initial attachment loss with most of the bone still intact in the furcation. No radiographic changes seen;

Grade II: The bone defect is definite horizontal bone loss that does not extend all the way through.

Vertical bone loss may also be present. There is an opening into the furca with a bony

wall at the deepest portion.

Grade III: Bone is lost across the whole width of the furcation so no bone is attached to the

furcation roof

Grade IV: Bone loss across the furcation, accompanied with gingival recession at the furcation, is clinically visible.

PERIODONTAL DISEASE CLASSIFICATION

I. Gingival Diseases

A. Dental plaque-induced gingival diseases*

- 1. Gingivitis associated with dental plaque only
- a. without other local contributing factors
- b. with local contributing factors
- 2. Gingival diseases modified by systemic factors
- a. associated with the endocrine system
- 1) puberty-associated gingivitis
- 2) Menstrual cycle-associated gingivitis
- 3) pregnancy-associated
- a) Gingivitis
- b) Pyogenic granuloma
- 4) diabetes mellitus-associated gingivitis
- b. associated with blood dyscrasias
- 5) leukaemia-associated gingivitis
- 6) Other
- 3. Gingival diseases modified by medications
- a. drug-influenced gingival diseases
- 1) drug-influenced gingival enlargements
- 2) drug-influenced gingivitis
- a) oral contraceptive-associated gingivitis
- b) Other
- 4. Gingival diseases modified by malnutrition
- a. ascorbic acid-deficiency gingivitis
- b. other

B. Non-plaque-induced gingival lesions

1Gingival diseases of specific bacterial origin

- a. Neisseria gonorrhoea-associated lesions
- b. Treponema pallidum-associated lesions
- c. streptococcal species-associated lesions
- d. other



- 2. Gingival diseases of viral origin
- a. herpes virus infections
- 1) Primary herpetic gingivostomatitis
- 2) Recurrent oral herpes
- 3) Varicella-zoster infections
- b. Other
- 3. Gingival diseases of fungal origin
- a. Candida-species infections
- 1) Generalized gingival candidosis
- b. linear gingival erythema
- c. histoplasmosis
- d. other
- 4. Gingival lesions of genetic origin
- a. hereditary gingival fibromatosis
- b. other
- 5. Gingival manifestations of systemic conditions
- a. mucocutaneous disorders
- 1) Lichen planus
- 2) Pemphigoid
- 3) Pemphigus vulgaris
- 4) Erythema multiforme
- 5) Lupus erythematosus
- 6) drug-induced
- 7) other
- b. allergic reactions
- 1) Dental restorative materials
- a) Mercury
- b) Nickel
- c) Acrylic
- d) Other
- 2) Reactions attributable to
- a) toothpastes/dentifrices
- b) mouthrinses/mouthwashes
- c) Chewing gum additives
- d) Foods and additives
- 3) Other
- 6. Traumatic lesions (factitious, iatrogenic, accidental)
- a. chemical injury
- b. physical injury
- c. thermal injury
- 7. Foreign body reactions
- 8. Not otherwise specified (NOS)

II. Chronic Periodontitis

- A. Localized
- B. Generalized



III. Aggressive Periodontitis

- A. Localized
- B. Generalized

IV. Periodontitis as a Manifestation of Systemic

Diseases

- A. Associated with haematological disorders
- 1. Acquired neutropenia
- 2. Leukaemia
- 3. Other
- B. Associated with genetic disorders
- 1. Familial and cyclic neutropenia
- 2 Down syndrome
- 3. Leukocyte adhesion deficiency syndromes
- 4. Papillon-Lefèvre syndrome
- 5. Chediak-Higashi syndrome
- 6. Histiocytosis syndromes
- 7. Glycogen storage disease
- 8. Infantile genetic agranulocytosis
- 9. Cohen syndrome
- 10. Ehlers-Danlos syndrome (Types IV and VIII)
- 11. Hypophosphatasia
- 12. Other
- C. Not otherwise specified (NOS)

V. Necrotizing Periodontal Diseases

- A. Necrotizing ulcerative gingivitis (NUG)
- B. Necrotizing ulcerative periodontitis (NUP)

VI. Abscesses of the Periodontium

- A. Gingival abscess
- B. Periodontal abscess
- C. Pericoronal abscess

VII. Periodontitis Associated With Endodontic Lesions

A. Combined Periodontics-endodontic lesions

VIII. Developmental or Acquired Deformities and Conditions

- A. Localized tooth-related factors that modify or predispose to plaque-induced gingival diseases/periodontitis
- 1. Tooth anatomic factors
- 2. Dental restorations/appliances
- 3. Root fractures



- 4. Cervical root resorption and cementum tears
- B. Mucogingival deformities and conditions around teeth
- 1. Gingival/soft tissue recession
- a. facial or lingual surfaces
- b. interproximal (papillary)
- 2. Lack of keratinized gingivae
- 3. Decreased vestibular depth
- 4. Aberrant frenum/muscle position
- 5. Gingival excess
- a. Pseudo pocket
- b. inconsistent gingival margin
- c. excessive gingival display
- d. gingival enlargement (See I.A.3. and I.B.4.)
- 6. Abnormal colour
- C. Mucogingival deformities and conditions on edentulous ridges
- 1. Vertical and/or horizontal ridge deficiency
- 2. Lack of gingivae/keratinized tissue
- 3. Gingival/soft tissue enlargement
- 4. Aberrant frenum/muscle position
- 5. Decreased vestibular depth
- 6. Abnormal colour
- D. Occlusal trauma
- 1. Primary occlusal trauma
- 2. Secondary occlusal trauma

Scope and Application	This CPG is intended for use by all health care workers in their daily care of patients who undergo dental/oral procedures
Effective Date	2010
Supercedes Policy Number	Not applicable
Review Responsibilities	The Chairperson of the Oral Health CSN will initiate the review of this guidelines every 3 years from the date of issue or as required.
Further Information	Oral Health CSN Chairperson

RESPONSIBILITY:

CPG Owner: National Oral Health CSN

CPG Writer: Ministry of Health **Date:** November 2010

Endorsed:



National Medicines & Therapeutic Committee, MOH

Date: 23 November 2010

Endorsed:

National Health Executive Committee, MOH

Date: 25 November 2010